<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164032</url>
  </required_header>
  <id_info>
    <org_study_id>INTO_humans</org_study_id>
    <secondary_id>2013-004463-32</secondary_id>
    <nct_id>NCT02164032</nct_id>
  </id_info>
  <brief_title>The Role of IntraNasal Insulin in Regulating HepaTic Lipid COntent in HUMANS</brief_title>
  <acronym>INTO_humans</acronym>
  <official_title>The Role of IntraNasal Insulin in Regulating HepaTic Lipid COntent in HUMANS a Randomized, Controlled, Double Blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) is a common human liver pathology, closely
      associated with the obesity pandemic and insulin resistance. In the insulin resistant state
      the liver remains sensitive to pro-lipogenic signals of insulin, which further promote lipid
      accumulation. Secretion of very-low-density-lipoproteins (VLDL), the main carriers of
      triglycerides (TG) in the plasma, is the principal pathway for the liver to mobilize and
      dispose of lipids. Thus, hepatic TG export must not be too low in order to prevent steatosis.
      Our preliminary data from animal experiments suggest that enhanced brain insulin signaling
      promotes hepatic VLDL secretion, and reduces lipid accumulation in the liver. It remains to
      be tested whether other insulin sensitive tissues, such as the myocardium or the skeletal
      muscle, are also affected. In humans, neuropeptides, including insulin, can be delivered to
      the brain via an intranasal (IN) route of administration, without causing relevant systemic
      side effects.

      Therefore, we hypothesize that by enhancing brain insulin signaling using chronic IN insulin
      administration hepatic TG export increases and prohibits lipid accumulation in the liver and
      other insulin sensitive tissues, such as the myocardium and the skeletal muscle.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in total lipid content in the liver</measure>
    <time_frame>one week before &amp; at baseline &amp; 1,2,3 and 4 weeks after intranasal insulin administration</time_frame>
    <description>1H magnetic resonance spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of hepatic Lipid composition</measure>
    <time_frame>one week before &amp; baseline &amp; 1,2,3 and 4 weeks after intranasal insulin administration</time_frame>
    <description>1H magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of myocardial lipid content</measure>
    <time_frame>baseline, 2 and 4 weeks after intranasal insulin administration</time_frame>
    <description>1H magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of myocardial lipid composition</measure>
    <time_frame>baseline, 2 and 4 weeks after intranasal insulin administration</time_frame>
    <description>1H magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of skeletal muscle lipid content</measure>
    <time_frame>baseline, 2 and 4 weeks after intranasal insulin administration</time_frame>
    <description>1H magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of lipid composition in skeletal muscle</measure>
    <time_frame>baseline, 2 and 4 weeks after intranasal insulin administration</time_frame>
    <description>1H magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in heart function</measure>
    <time_frame>baseline, 2 and 4 weeks after intranasal insulin administration</time_frame>
    <description>magnetic resonance imaging</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes of parameters of glucose and lipid metabolism</measure>
    <time_frame>one week before &amp; baseline &amp; 1,2,3 and 4 weeks after initiation of intranasal insulin administration</time_frame>
    <description>fasting Glucose, HbA1c, Cholesterol, LDL, HDL, TGs, non-HDL Cholesterol, FFAs</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid composition in plasma</measure>
    <time_frame>one week before &amp; at baseline &amp; 1,2,3 and 4 weeks after intranasal insulin administration</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Insulin dilution buffer</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During a subsequent 4-week treatment phase subjects will be randomly assigned to receive intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia.
Ectopic lipid content and heart function will be assessed weekly by non-invasive 1H magnetic resonance spectroscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal Insulin administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During a subsequent 4-week treatment phase subjects will be randomly assigned to receive intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia.
Ectopic lipid content and heart function will be assessed weekly by non-invasive 1H magnetic resonance spectroscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal insulin administration</intervention_name>
    <description>intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia</description>
    <arm_group_label>Intranasal Insulin administration</arm_group_label>
    <other_name>insulin Actrapid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Dilution Buffer (Novo Nordisk)</intervention_name>
    <description>intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia</description>
    <arm_group_label>Insulin dilution buffer</arm_group_label>
    <other_name>vehicle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1H magnetic resonance spectroscopy</intervention_name>
    <description>1H MR spectroscopy and imaging will be performed on the on on the 3.0-T Tim Trio System (Siemens Erlangen Germany). MR Spectroscopy and imaging measurements will last no more than 90 minutes all together.</description>
    <arm_group_label>Insulin dilution buffer</arm_group_label>
    <arm_group_label>Intranasal Insulin administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 22 - 27 kg/m2

          -  Age between 18 - 65 years

          -  Male sex

        Exclusion Criteria:

          -  smoking

          -  regular medication

          -  metabolic or liver illnesses

          -  tendency towards claustrophobia

          -  Chronic sinusitis, diagnosed nasal polyposis, diagnosed severe septum deviation

          -  metal devices or other magnetic material in or on the subjects body which will be
             hazardous for NMR investigation [heart pacemaker, brain (aneurysm) clip, nerve
             stimulators, electrodes, ear implants, post coronary by-pass graft (epicardial pace
             wires), penile implants, colored contact lenses, patch to deliver medications through
             the skin, coiled spring intrauterine device, vascular filter for blood clots,
             orthodontic braces, shunt-spinal or ventricular, any metal implants (rods, joints,
             plates, pins, screws, nails, or clips), embolization coil, or any metal fragments or
             shrapnel in the body].
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Krebs, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Of Vienna, Department of Internal Medicine III</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Michael Krebs</investigator_full_name>
    <investigator_title>Prof. MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 22, 2017</submitted>
    <returned>April 6, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

